Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)
- Conditions
- Interventions
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Canadian Heart Research Centre
- Target Recruit Count
- 391
- Registration Number
- NCT00131664
- Locations
- 🇨🇦
Canadian Heart Research Centre, Toronto, Ontario, Canada
Insulin Resistance and Testosterone in Women
- Conditions
- Interventions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 35
- Registration Number
- NCT00123110
- Locations
- 🇺🇸
University of Pennsylvania Clinical and Translational Research Center, Philadelphia, Pennsylvania, United States
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
- Conditions
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1035
- Registration Number
- NCT00121641
- Locations
- 🇨🇳
Local Institution, Taipei, Taiwan
South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus
- Conditions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2008-06-19
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT00121966
- Locations
- 🇩🇰
Diabetes Research Center, Odense, Denmark
Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
- Conditions
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2008-12-08
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 100
- Registration Number
- NCT00118950
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Denmark
Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
- Conditions
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2008-12-08
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 102
- Registration Number
- NCT00118963
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Denmark
Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2008-12-08
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 100
- Registration Number
- NCT00118937
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2005-05-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 218
- Registration Number
- NCT00111631
Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)
- Conditions
- First Posted Date
- 2005-05-16
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT00110851
- Locations
- 🇺🇸
Endocrine Clinical Research, Winter Park, Florida, United States
🇺🇸Neem Research Group, Columbia, South Carolina, United States
🇺🇸Phoenix Internal Medicine Associates, Waterbury, Connecticut, United States
Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance
- Conditions
- Interventions
- First Posted Date
- 2005-04-18
- Last Posted Date
- 2008-04-25
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 48
- Registration Number
- NCT00108615
- Locations
- 🇺🇸
Central Arkansas Veterans HCS, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.